brexpiprazole / Generic mfg. - LARVOL DELTA

Drugs for dementia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Movement Disorders • Parkinson's Disease

Design, Optimization, and In Vitro Evaluation of Lactoferrin-Coated Brexpiprazole-Loaded Nanostructured Lipid Carriers for Brain Targeting. (PubMed, AAPS PharmSciTech) - "The integrated DoE-Assessment of a predicted model-based successful optimization of lactoferrin-functionalized extended release Brexpiprazole-loaded NLCs with 132.8 ± 2.4 nm, and zeta potential -26.2 ± 1.3 mV, which demonstrated strong compatibility, sustained release, and promising potential for targeted nose-to-brain delivery of Brexpiprazole."

Journal • Preclinical

Female Sexual Dysfunction Induced by Second-Generation Antipsychotic Drugs-A Disproportionality Analysis Based on the FAERS Database. (PubMed, Schizophr Bull) - "This pharmacovigilance study highlights significant associations between specific SGAs and female sexual dysfunction. Disproportionality signals vary by drug, symptom type, and prolactin-related mechanisms. Clinicians should consider sexual side effects in treatment decisions and monitor patients accordingly. Further prospective studies are warranted."

Journal • CNS Disorders • Mental Retardation • Psychiatry • Sexual Disorders

REAL WORLD LONGITUDINAL DATA FROM ALZ-NET: DEMOGRAPHICS, CLINICAL AND SAFETY OUTCOMES IN PARTICIPANTS RECEIVING BETA AMYLOID TARGETING MONOCLONAL ANTIBODIES (ADPD 2026) - "Of those enrolled, 1,362 are on lecanemab; 405 are on donanemab; and 21 are on brexpiprazole. ALZ-NET is a resource for collecting and assessing RWD from communities across the country. Future work will assess adherence to FDA prescribing labels and Appropriate Use Recommendations in real-world practice and evaluate the associations between baseline patient characteristics and long-term clinical and safety outcomes in patients treated with novel therapies."

Clinical • Real-world • Real-world evidence • Alzheimer's Disease • CNS Disorders • Dementia

Efficacy and safety of brexpiprazole in early-episode schizophrenia: post hoc analysis of Phase 3 clinical trials in adults and adolescents. (PubMed, Psychiatry Res) - P3 | "This analysis expands the evidence base for brexpiprazole in schizophrenia by demonstrating efficacy in patients who are early in their disease course. The safety profile of brexpiprazole was consistent with previous clinical trials."

Clinical • Journal • P3 data • Retrospective data • CNS Disorders • Insomnia • Psychiatry • Schizophrenia • Sleep Disorder

COMPARATIVE EFFICACY AND SAFETY OF LUMATEPERONE AND OTHER ATYPICAL ANTIPSYCHOTICS APPROVED AS ADJUNCTIVE THERAPY FOR MAJOR DEPRESSIVE DISORDER: A NETWORK META-ANALYSIS (ISPOR 2026) - "This network meta-analysis (NMA) compared efficacy and safety of lumateperone with other approved atypical antipsychotics: aripiprazole, brexpiprazole, cariprazine, and quetiapine XR for MDD with inadequate response to antidepressants (ADT). Ten short-term, randomized, double-blind, placebo-controlled registration trials formed a star-shaped network of 11 treatment- and dose-specific nodes anchored on placebo+ADT. In this NMA, lumateperone demonstrated a favorable efficacy profile versus other approved adjunctive antipsychotics, with no increased risk of weight gain. Balancing efficacy and safety is crucial when selecting adjunctive antipsychotic treatment for MDD."

Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Antipsychotics in Children and Adolescents with Schizophrenia-Spectrum Disorders: A Systematic Review, Meta-Analysis, and Long-Term Prospective Evidence. (PubMed, J Child Adolesc Psychopharmacol) - "Several SGAs produce short-term symptom reductions versus placebo in children and adolescents with schizophrenia-spectrum disorders, with heterogeneity in TEAE risk across agents. Evidence for long-term maintenance and continuation remains limited, underscoring the need for adequately powered randomized continuation trials to guide sustained treatment in this population."

Journal • Retrospective data • Review • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Synergistic Effect of Combination Treatment of Brexpiprazole and Nalmefene on Ethanol Intake in Rats. (PubMed, Neuropsychopharmacol Rep) - "These data suggest that brexpiprazole may have the potential to decrease alcohol intake in AUD patients. In addition, brexpiprazole may have a synergistic therapeutic effect with nalmefene in those patients."

Journal • Preclinical • Addiction (Opioid and Alcohol)

Investigational drugs in PTSD. (PubMed, Neuropsychopharmacology) - "Despite decades of research, only sertraline and paroxetine are FDA-approved, both with modest efficacy...Ketamine produces symptom reductions within hours, MDMA-assisted psychotherapy has demonstrated Phase 3 efficacy, and neurosteroids offer novel approaches to targeting hyperarousal...Brexpiprazole's recent FDA rejection, despite supportive early data, underscores persistent regulatory hurdles. While traditional approaches remain standard of care, breakthrough therapies represent paradigm shifts toward disease modification. Future progress depends on biomarker-guided precision medicine, novel trial designs to mitigate placebo effects, and integration of pharmacologic innovations with evidence-based psychotherapies."

Journal • Review • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry • B3GAT1

HEALTHCARE RESOURCE UTILIZATION IN LONG-TERM CARE RESIDENTS WITH AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE TREATED WITH BREXPIPRAZOLE (ISPOR 2026) - "These results suggest that brexpiprazole treatment may help improve LTC HCRU event rates and ease LTC professional caregiver burden by reducing agitation symptoms and associated reporting burden faced by professional caregivers of individuals with agitation associated with dementia due to Alzheimer's disease."

HEOR • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Dose-dependent Efficacy and Safety of Brexpiprazole in Agitation Associated with Dementia in Alzheimer's Disease: A Systematic Review and Meta-analysis (AAN 2026) - "Brexpiprazole effectively reduces agitation in AD without major safety concerns, though mild motor effects were noted. Study limitations include moderate heterogeneity and short trial durations. Future research should explore long-term outcomes and patient stratification."

Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Dementia

Behavioral Neurology and Neuropsychiatry Section Poster Tour (AAN 2026) - "If you are interested in attending, visit the poster hall and look for the tour guide holding the yellow Poster Tour sign. Featured abstracts:Anti-tau Therapies in Alzheimer's Disease: Systematic Review and Meta-analysis of Advanced-phase Randomized Clinical TrialsTop-line Results from evoke and evoke+: Two Phase 3, Randomized, Placebo-controlled Trials of Semaglutide in Participants with Early-stage Symptomatic Alzheimer's DiseaseRepurposed Drugs for Alzheimer's Disease: Integrating Mechanistic Efficacy and Global Feasibility Through a Translational Decision MatrixNovel Mechanistic Roles for TMEM106B in Regulating Lysosomal Inter-organelle Contact Sites and Misregulation in Frontotemporal DementiaDifferential Response to Transcranial Direct Current Stimulation Across Primary Progressive Aphasia Subtypes: A Case Study AnalysisDose-dependent Efficacy and Safety of Brexpiprazole in Agitation Associated with Dementia in Alzheimer's Disease: A Systematic..."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Frontotemporal Lobar Degeneration • Psychiatry

Effects of Adjunctive Brexpiprazole with SSRI Treatment on Anxiety and Sleep Architecture in Mice. (PubMed, Int J Neuropsychopharmacol) - "In this study, we demonstrated that the combination of brexpiprazole and paroxetine produced anxiolytic-like effects and altered sleep architecture in mice. Furthermore, the anxiolytic-like effect of the combination suggests that brexpiprazole's α2C AR antagonistic activity may be one of several plausible contributors. Adjunctive brexpiprazole may influence anxiety and sleep architecture, potentially contributing to the management of residual symptoms in MDD."

Journal • Preclinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Sleep Disorder

Brexpiprazole for treating agitation in different groups of people with Alzheimer's dementia: a plain language summary. (PubMed, Neurodegener Dis Manag) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders • Dementia

A physics-informed graph neural network to approximate docking-based binding affinity for DYRK2 in Alzheimer's drug repurposing. (PubMed, Sci Rep) - "Due to the limited number of ligands (n = 4 FDA-approved AD drugs: brexpiprazole, donepezil, galantamine, rivastigmine), the results should be viewed as agreement with computational references rather than generalizable predictive performance. Overall, PhysDual-GCN offers a biologically meaningful and explainable approximation tool for DYRK2 interaction scoring. While the present results are constrained by the small number of compounds and the absence of 3D protein features, the approach establishes a foundation for future large-scale, experimentally validated studies in AD drug repurposing."

Journal • Alzheimer's Disease • CNS Disorders

Antipsychotic treatment patterns and cardiometabolic medicine use: current real-world evidence. (PubMed, Epidemiol Psychiatr Sci) - "Use of cardiometabolic medicines is increased among people on long-term antipsychotic treatment. These results highlight the need for active monitoring for cardiometabolic adverse effects, with antipsychotic cessation where possible, or timely interventions to limit morbidity."

HEOR • Journal • Real-world evidence • Retrospective data • Cardiovascular • CNS Disorders • Metabolic Disorders

Lundbeck reports Q4 results with mixed performance, issues 2026 outlook (Investing.com) - "The company’s key products Vyepti, Abilify franchise, and Trintellix performed ahead of expectations, while Rexulti missed consensus estimates by 9%. Lower gross margins were more than offset by reduced SG&A spending, contributing to the EBITDA beat...While the company appears on track to meet its mid-term targets through 2027, it faces revenue challenges beyond that period as key products Abilify Maintena and Trintellix/Brintellix face generic pressure starting in 2026."

Commercial • Alzheimer's Disease • Attention Deficit Hyperactivity Disorder • Depression • Migraine • Pain • Schizophrenia

Third-Generation Antipsychotics as Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Narrative Review of Efficacy and Tolerability. (PubMed, Biomedicines) - "Two cohort studies were included on brexpiprazole, with no active or placebo comparator. The current state of evidence supports the clinical utility of TGAs, particularly aripiprazole, in augmenting SRI treatment in patients with refractory OCD. Evidence regarding cariprazine and lumateperone is scarce, but still contributes to the discussion on the use of TGAs in OCD."

Journal • CNS Disorders • Mental Retardation • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

Clinical Effects of Recently Developed Antipsychotic Drugs in Schizophrenia. (PubMed, Cent Nerv Syst Agents Med Chem) - "Promising new antipsychotic drugs include cariprazine, brexpiprazole, lumateperone, ulotaront, and xanomeline combined with trospium. Phase 3 clinical studies have shown therapeutic effects superior to those achieved with second-generation antipsychotic drugs."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Evaluation of the Safety of Taking Brexpiprazole During the Lactation Period. (PubMed, Breastfeed Med) - "This study suggests that BPZ monotherapy (1-2 mg/day) during lactation does not lead to withdrawal symptoms or serious adverse events in newborns or infants within the first month postpartum. This initial evidence may help inform breastfeeding decisions among mothers receiving BPZ monotherapy."

Journal • Acne Vulgaris • CNS Disorders • Psychiatry

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia (clinicaltrials.gov) - P3 | N=295 | Completed | Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Active, not recruiting ➔ Completed | Trial completion date: Aug 2025 ➔ Apr 2025

Trial completion • Trial completion date • CNS Disorders • Psychiatry • Schizophrenia

Brexpiprazole inhibits EMT and migration of colorectal cancer cells by downregulating the SREBP1/SNAI1 signaling pathway. (PubMed, Front Oncol) - "On the other hand, in vivo experiments revealed that brexpiprazole significantly inhibited the formation of CRC lung metastases, suppressed the expression of SREBP1(m), SNAI1and MMP9, and upregulated the expression of E-Cad and ZO1. Brexpiprazole inhibits the migration, invasion and metastasis of CRC cells by inhibiting the SREBP1/SNAI1 signalling pathway and downregulating the expression of EMT-related factors."

Journal • Colorectal Cancer • Oncology • Solid Tumor • CAD • ICAM1 • MMP9 • SNAI1 • TJP1

A Randomized Controlled Trial of Brexpiprazole versus Aripiprazole in the Treatment of Major Depressive Disorder with Psychotic Symptoms in Adolescents (ChiCTR) - P=N/A | N=80 | Not yet recruiting | Sponsor: Shandong mental health center; Shandong mental health center

New trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Dose-Dependent efficacy and safety of Brexpiprazole in agitation associated with dementia in Alzheimer's disease: A systematic review and meta-analysis. (PubMed, Neurol Sci) - "Brexpiprazole effectively reduces agitation in AD without major safety concerns, though mild motor effects were noted. Study limitations include moderate heterogeneity and short trial durations. Future research should explore long-term outcomes and patient stratification."

Clinical • Journal • Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Dementia • Psychiatry

Efficacy of Brexpiprazole in Participants with Agitation Associated with Dementia Due to Alzheimer's Disease: Pooled Analysis of Randomized Controlled Trials. (PubMed, Clin Drug Investig) - P3 | "Brexpiprazole 2 or 3 mg/day reduced agitation symptoms compared with placebo over 12 weeks in this large, pooled sample of participants with dementia due to Alzheimer's disease."

Clinical • Journal • Retrospective data • Alzheimer's Disease • CNS Disorders • Dementia